The GREACE study emphasizes the urgent need for a wider use of lipid-lowering drugs in high-risk patients. Evaluation (GREACE) Study consisted of patients with coronary heart disease (CHD) followed up for three years1. The patients were randomised to either. Our post-hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study was done to address this issue. Because of the.
|Published (Last):||15 December 2013|
|PDF File Size:||5.71 Mb|
|ePub File Size:||20.32 Mb|
|Price:||Free* [*Free Regsitration Required]|
The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study – UCL Discovery
I am an author of this article. A summary of the content will be automatically included.
Consider the following examples, but note that this is not an exhaustive list: By posting or uploading Material you warrant and represent that: F does not store recipient email addresses. Erratum in Curr Med Res Opin. This entry form currently does not support special characters.
F does not claim any ownership in the Material that you or any other user posts. These terms shall be governed by and construed in accordance with Studj Law.
Material ggeace not reflect the views or opinions of F, its agents or affiliates. All patients were followed up for a mean period of 3 years. I am a Faculty Member who recommended this article. By posting Material you grant to F an irrevocable non-exclusive royalty-free license to keep a copy of Material for a reasonable period and as necessary to enable it to comply with its legal obligations.
You are entitled to post or upload the Material on the website and have all necessary licenses and consents to do so; the Material does not infringe any intellectual property right, including without limitation copyright, patent or trademark, or other proprietary right of any third party; the Material does not contain sttudy defamatory, libellous, offensive, indecent or otherwise unlawful material or material which is an invasion of privacy; the Material does not contain any contaminating or destructive features or devices such as viruses, time bombs or coding designed to interrupt, destroy or limit the functionality of this website or any of this website’s user’s computer equipment or software; the Material will not be used to solicit or promote business or custom or present commercial activities or unlawful activity; and the Material is in compliance with all applicable laws.
You work at the same institute as any of the authors. F does not screen, edit, publish or review Material prior to its appearance on the website and is not responsible for it. You are a close professional associate of any of the authors e. Examples of ‘Financial Competing Interests’ You expect to receive, or in the past 4 years have received, any of the following from any grreace organization that may gain financially from your submission: Register for day free trial Registration is free and only takes a moment, or subscribe for unlimited access.
You may not use the website for any unlawful purpose, including without limitation, to upload, post, download or otherwise use any Material that you do not have the copyright owners permission to so upload, post, download or otherwise use, or that would result in you being in breach of these terms and conditions.
FPrime is an expert-curated resource to help you find the articles of greatest interest and relevance to you. Institutional access Recommend FPrime to your librarian or information manager to request an extended free trial for all users at your institution. During this study Certain parts of this website offer the opportunity for users to post opinions, information and material including without limitation academic papers and data ‘Material’ in areas of the website.
Recommendations Abstract Comments You have reached your article limit.
The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. – Semantic Scholar
You have a close personal relationship e. Examples of ‘Non-Financial Competing Interests’ Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. I would like to receive updates when further comments, recommendations, or dissenting opinions are publishing on this article.
Treatment with atorvastatin is well tolerated and cost-effective. In detail, atorvastatin reduced, in comparison to ‘usual’ care, total mortality RR 0. However, there is no long-term survival study that evaluated this statin. Secondary endpoints were the safety and efficacy of the hypolipidaemic drugs as well as the cost-effectiveness of atorvastatin.
GREACE (GREek Atorvastatin Coronary-heart-disease Evaluation) study
F reserves the right to monitor all Material and to remove any Material which it considers in its absolute discretion to be unlawful, inappropriate, offensive or otherwise in breach of these Terms and Conditions. Don’t have an account? Recommend to your librarian. To assess the effect of atorvastatin on morbidity and mortality total and coronary of patients with established coronary heart disease CHDconsecutive patients were randomised either to atorvastatin or to ‘usual’ medical care.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. User comments must be in English, comprehensible and relevant to the article under discussion. Consider the following examples, but note that this is not an exhaustive list:.
Comment in Curr Med Res Opin. You are an Editor for the journal in which the article is published. Primary endpoints of the study were defined as death, non-fatal myocardial infarction, unstable angina, congestive heart failure, revascularisation coronary morbidity and stroke. All subgroups of patients women, those with diabetes mellitus, arterial hypertension, age 60 to 75 years, congestive heart failure, recent unstable angina or prior revascularisation benefited from treatment with atorvastatin.
This Agreement shall begin on the date hereof. Atorvastatin is very effective in reducing plasma low-density gresce cholesterol LDL-C levels. Withdrawal of patients because of side-effects from the atorvastatin group was low 0.
The use of certain tools provided by this website is subject to additional Terms and Conditions. Neither of the above.